What is the recommended treatment for social anxiety disorder?

Treatment of Social Anxiety Disorder

For adults with social anxiety disorder, start with either an SSRI (escitalopram, paroxetine, or fluvoxamine) or individual cognitive behavioral therapy (CBT) based on the Clark & Wells or Heimberg model—both are equally effective first-line options. 1

Pharmacotherapy Approach

First-Line Medications

SSRIs are the recommended first-line pharmacological treatment 1:

• Escitalopram, paroxetine, or fluvoxamine are specifically covered by insurance in Japan and should be your initial choices 1
• Sertraline is equally effective but may not be covered by insurance in all regions 1
• Venlafaxine (SNRI) is also suggested as first-line, with comparable efficacy to SSRIs 1

The evidence supporting these medications comes from 26 RCTs for SSRIs and 5 RCTs for SNRIs, though the overall certainty of evidence is rated as "low" with "weak" strength of recommendation 1. Despite this grading, these remain the standard of care globally.

International Guideline Comparison

Other major guidelines align with these recommendations 1:

• NICE (UK): Lists escitalopram and sertraline as first-line
• German S3: Recommends escitalopram, paroxetine, sertraline, and venlafaxine
• Canadian CPG: Includes all the above SSRIs plus pregabalin as first-line options

Second-Line Options

If SSRIs/SNRIs fail or are not tolerated 1:

• Benzodiazepines (alprazolam, bromazepam, clonazepam) - use cautiously due to dependence risk
• Pregabalin or gabapentin - antiepileptic analogs with anxiolytic properties
• Avoid: Beta-blockers (atenolol, propranolol) are only effective for performance-limited anxiety, not generalized SAD 1

Psychotherapy Approach

Cognitive Behavioral Therapy (CBT)

Individual CBT specifically designed for SAD is the recommended psychotherapy 1:

Structure and Duration:

• 14 sessions over 4 months
• 60-90 minutes per individual session
• Individual therapy is prioritized over group therapy due to superior clinical and cost-effectiveness 1

Two Evidence-Based Models:

1. Clark & Wells Model includes:

   • Psychoeducation on social anxiety
   • Cognitive restructuring
   • Gradual exposure to feared situations
   • Review and modification of core beliefs
   • Relapse prevention

2. Heimberg Model follows similar components with structured exposure exercises 1

Alternative: Supported Self-Help

If the patient refuses face-to-face CBT, offer supported self-help based on CBT principles 1:

• Approximately 9 sessions over 3-4 months
• Uses self-help materials with therapist support
• This is a "weak" recommendation but provides an option when traditional CBT is unavailable

Monotherapy vs. Combination Therapy

There is no recommendation for combining pharmacotherapy and psychotherapy 1. The evidence does not demonstrate clear superiority of combination treatment over either modality alone. Choose one approach initially based on:

• Patient preference
• Availability of skilled CBT therapists
• Severity of symptoms
• Presence of comorbidities (SSRIs may be preferred if treating comorbid depression)

Important Clinical Considerations

Common Pitfalls to Avoid:

1. Don't use beta-blockers for generalized SAD - they only work for performance-limited anxiety (public speaking) 1
2. Avoid quetiapine, imipramine, and levetiracetam - negative evidence for efficacy 1
3. Monitor treatment response - approximately 60% of untreated patients have persistent symptoms for years 1
4. Continue medications for 6-12 months after remission to prevent relapse 2

Special Populations Excluded from Guidelines:

The recommendations above apply to adults ≥18 years without 1:

• Comorbid schizophrenia, bipolar disorder, or substance use disorders
• Pregnancy or potential pregnancy
• Active suicidal ideation
• Significant intellectual disability
• Unstable medical illness

Treatment Monitoring

Response should be evaluated by a physician with expertise in anxiety disorders 1. If inadequate response occurs after an adequate trial (typically 8-12 weeks at therapeutic dose), consider switching to another SSRI/SNRI rather than immediately combining treatments 1.

Emerging Evidence

Recent research suggests cannabidiol and d-cycloserine show promise, but these are not yet recommended in clinical guidelines pending further evidence 3. Paroxetine specifically showed the strongest effect size in network meta-analysis compared to other agents 4.

The choice between pharmacotherapy and psychotherapy should be made through shared decision-making, considering that both have comparable efficacy but different adverse effect profiles and accessibility 1.